News | Computed Tomography (CT) | November 19, 2020

CurveBeam Announces FDA 510(K) Clearance for HiRise Weight-bearing CT System

CurveBeam announced the HiRise, its weight bearing CT (WBCT) imaging system for the entire lower extremity, has received FDA 510(K) clearance.

November 19, 2020 — CurveBeam announced the HiRise, its weight bearing CT (WBCT) imaging system for the entire lower extremity, has received FDA 510(K) clearance.

CurveBeam is a leader in weight bearing CT imaging for the orthopedic extremities. CurveBeam systems offer a wide patient platform that lets patients stand naturally on both feet during a scan. CurveBeam’s HiRise can scan anywhere along the lower extremity from the hip and pelvis to the feet. WBCT imaging of the hip and pelvis is a novel application not previously available in any system.

“CurveBeam’s mission is to be responsive to crucial but unmet diagnostic needs of the specialties it serves, and introduction of the HiRise device is the latest transformational step in that direction,” said CurveBeam President and CEO Arun Singh. “This system literally achieves new heights in point of care advanced orthopedic imaging.”

Two HiRise systems were installed for investigational studies prior to FDA clearance at University of Iowa Carver School of Medicine’s Department of Orthopedics and Rehabilitation in Iowa City, IA, and at Tennessee Orthopaedic Clinics (TOC) in Knoxville, TN.

The HiRise gantry tilts for upper extremity imaging and supine lower leg imaging.

Researchers at University of Iowa are using the HiRise for multiple research studies, including examining hip dysplasia in functional position and evaluating wrist injuries in gymnasts.  

“The HiRise promises to revolutionize our biomechanical understanding of the entire lower extremity the same way previous generations of CurveBeam’s weight bearing CT systems enabled better investigation into the foot, ankle and knee,” said Cesar de Cesar Netto, M.D., Ph.D., Assistant Professor of Orthopedics and Rehabilitation at University of Iowa.

CurveBeam’s systems utilize cone beam CT technology and are designed for the orthopedic point-of-care setting. The HiRise plugs into a standard wall outlet, requires minimal shielding, and is easy to operate.

CurveBeam announced CE Marking for the HiRise in October.

For more information: www.curvebeam.com

Related Content

Chest X-ray image of patient with lung injury due to vaping. Image courtesy of UC Regents #COVID19 #pandemic

Chest X-ray image of patient with lung injury due to vaping. Image courtesy of UC Regents

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — A UC Davis Health ped
1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well

1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well as elevated Lac. B, A patient with COVID-19 after recent PEA cardiac arrest with subtle FLAIR hyperintense white matter changes also shows elevated Cho/Cr and decreased NAA/Cr ratios. However, these derangements are less severe than in the patient in A. There is no clear elevation of Lac. C, A patient with COVID-19 without encephalopathy or recent severe hypoxia has normal Cho/Cr, with mildly decreased NAA/Cr and no lactate elevation. Cho, Choline; NAA, N-Acetyl-Aspartate; mI, Myo-Inositol; Lac, Lactate; Glx, Glutamate + Glutamine. Image courtesy of AJNR

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — One of the first spectroscopic imaging-based studies of neurological injury in...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
Videos | November 18, 2020
An example of a COVID-19 (SARS-CoV-2) pneumonia on chest computed tomography (CT) scan.
In partnership with Imaging Technology News, we collected feedback from more than 100 diagnostic imaging professionals including healthcare executives, radiology and IT leaders, radiologists, technologists, clinicians, and industry vendors regarding their perspective of the new virtual format, whether they’re attending, and if so what they’re hoping to get out of it. #RSNA20
Feature | Radiology Business | November 17, 2020 | By Laurie Lafleur
SyntheticMR, an innovative software solutions company for magnetic resonance imaging (MRI) announced today the company filed a 510(k) submission for its musculoskeletal solutions package, SyMRI MSK.
News | Magnetic Resonance Imaging (MRI) | November 17, 2020
November 17, 2020 — SyntheticMR, an innovative software solutions company for...